US2012294901A1PendingUtilityA1

Novel cochleate formulations

57
Assignee: ZARIF LEILAPriority: Jan 22, 1999Filed: Apr 6, 2012Published: Nov 22, 2012
Est. expiryJan 22, 2019(expired)· nominal 20-yr term from priority
A61P 9/10A61P 37/06A61P 31/10A61P 35/00A61P 31/04A61P 31/12A61P 25/20A61P 29/00A61K 31/713Y10S436/829A61K 31/11A61K 31/20Y10T428/2984A61K 36/54A61P 23/00A61K 9/1274A61K 31/472A61K 38/13A61K 31/704A61K 31/496A61K 31/07A61K 31/7048
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca 2+ or Zn 2+ , forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.

Claims

exact text as granted — not AI-modified
1 . A cochleate composition comprising a population of cochleates, wherein the cochleates comprise:
 a negatively charged first lipid;   a divalent cation or higher valency cation and   an additional biologically relevant molecule,   
       wherein the mean particle size of the cochleates is less than one micron. 
     
     
         2 - 72 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.